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Empirical evidence for definitions of episode,
remission, recovery, relapse and recurrence in
depression: a systematic review
P. L. de Zwart1*, B. F. Jeronimus1,2 and P. de Jonge1,2
1 University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and
Emotion Regulation (ICPE), Groningen, The Netherlands
2 University of Groningen, Faculty of Behavioural and Social Sciences, Department of Developmental Psychology, Groningen, The Netherlands
Aims. For the past quarter of a century, Frank et al.’s (1991) consensus-based definitions of major depressive disorder
(MDD) episode, remission, recovery, relapse and recurrence have been the paramount driving forces for consistency in
MDD research as well as in clinical practice. This study aims to review the evidence for the empirical validation of Frank
et al.’s proposed concept definitions and to discuss evidence-based modifications.
Methods. A literature search of Web of Science and PubMed from 1/1/1991 to 08/30/2017 identified all publications
which referenced Frank et al.’s request for definition validation. Publications with data relevant for validation were
included and checked for referencing other studies providing such data.
Results. A total of 56 studies involving 39 315 subjects were included,mainly presenting data to validate the severity and
duration thresholds for defining remission and recovery. Most studies indicated that the severity threshold for defining
remission should decrease. Additionally, specific duration thresholds to separate remission from recovery did not add
any predictive value to the notion that increased remission duration alleviates the risk of reoccurrence of depressive symp-
toms. Only limited data were available to validate the severity and duration criteria for defining a depressive episode.
Conclusions. Remission can best be defined as a less symptomatic state than previously assumed (Hamilton Rating
Scale for Depression, 17-item version (HAMD-17) 44 instead of 47), without applying a duration criterion.
Duration thresholds to separate remission from recovery are not meaningful. The minimal duration of depressive symp-
toms to define a depressive episode should be longer than 2 weeks, although further studies are required to recommend
an exact duration threshold. These results are relevant for researchers and clinicians aiming to use evidence-based
depression outcomes.
Received 1 November 2017; Accepted 23 April 2018; First published online 17 May 2018
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Introduction
Major depressive disorder (MDD) is a common, often
chronic and recurrent condition, marked by persistent
suffering and poor overall health and with deleterious
effects on psychosocial, academic, vocational and fam-
ily functioning. MDD is one of the most prevalent
mental disorders and the leading cause of disability
worldwide (World Health Organization, 2017), with
lifetime prevalence estimates ranging from 7% to
21% (Kessler & Bromet, 2013).
In 1991, the MacArthur Foundation Network on the
Psychobiology of Depression concluded that the ran-
domness with which investigators referred to key
changes in clinical status of individuals with depres-
sion led to considerable confusion in the literature
(Prien et al. 1991). Subsequently, a task force was
initiated to achieve consensus about the definition of
key stages, change points and outcome definitions
for MDD among clinical investigators and practicing
clinicians. The resulting report by Frank et al. (1991)
defined conceptualisations of an MDD episode, remis-
sion, recovery, relapse and recurrence (see Fig. 1 and
supplementary Table) by a set of five parameters or
thresholds: two severity scores (cut-offs for ‘asymp-
tomatic’ and fully symptomatic ranges) and three
durations (minimal consecutive time durations in the
fully or a-symptomatic range before an episode, remis-
sion, or recovery can be declared).
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Specific consensus-based recommendations for
these thresholds were provided in Frank et al.’s
(1991) report and revised in a follow-up report by
Rush et al. (2006). Both reports explicitly requested
empirical validations of these now widely used
consensus-based definitions. Therefore, the present
paper reviews the accumulated evidence over the
past 27 years to validate the proposed conceptualisa-
tions and operationalisations and to provide sugges-
tions for future avenues.
Conceptual discussion
Here we focus on conceptualisations of MDD episode,
remission, recovery, relapse and recurrence by Frank
et al. (1991, see supplementary Table), which are
based exclusively on severity (number/intensity) and
duration of clinical symptoms, and each has its own
rationale and clinical implications. An MDD episode
means that illness is present and that treatment is indi-
cated. When the state of remission (a relatively brief
period without clinically relevant symptoms during
or at the end of an episode) is reached, no intensified
treatment regimen is required or justified. A recovery
(a sustained period of absence of clinically relevant
symptoms, i.e. a sustained remission) means that the
episode has ended and treatment can be discontinued
or aimed at preventing subsequent episodes. Relapse/
recurrence imply a return of symptoms during remis-
sion/recovery, respectively, and indicate a need for
treatment intensification. The implicit distinction
between relapse and recurrence is that a relapse is
thought to be a return of symptoms of an ongoing epi-
sode that was symptomatically suppressed, whereas a
recurrence represents an entirely new episode.
Importantly, these concepts can only have the
ascribed interpretations and treatment implications if
they have substantial predictive value for a future
course. For example, treatment is indicated for those
experiencing an episode because they have a worse
prognosis than those who are experiencing symptoms
that do not meet episode criteria. Therefore, the oper-
ationalisations of these concepts (i.e. the choice of
severity and duration thresholds) should be chosen
in such a way that they have optimal prognostic
significance.
In particular, it should be possible to distinguish
remission from recovery (and therefore relapse from
recurrence), which are different only in their duration,
by a difference in prognosis. The hypothesis is that
those in remission have not (yet) fully recovered
from the latently present episode (i.e. they are still
undergoing a healing process) and therefore have a
relatively high relapse rate compared with those who
recovered. Those who recovered have a low recurrence
rate that is no longer dependent on the time since their
last episode and equal to the incidence rate of a risk
factor-comparable population who never experienced
an episode. Similarly, in cancer research, ‘full remis-
sion’ is defined as the period during which any sign
of the disease is lacking, but during which a patient
is particularly vulnerable for a relapse of the tumour
since latent disease might still be present. When the
remission is of sufficiently long duration, the patient
can be (retrospectively) considered to be recovered or
‘cured’ as the passing of even more time does not pro-
vide additional protection to disease recurrence, the
risk of which is similar to the incidence risk of a com-
parable healthy population.
Some of the clinical status concepts that are the sub-
ject of this review are also defined in the Diagnostic
and Statistical Manual of mental disorders (DSM-5;
American Psychiatric Association, 2013) and the
International Classification of Diseases (ICD-10;
Fig. 1. Time course of depressive symptomatology in a hypothetical patient, showing an MDD episode, remission, relapse,
recovery and recurrence. These stages are operationalised using two severity criteria (S1, S2), and three duration criteria (D, E, F).
S1: Severity threshold separating asymptomatic from partially symptomatic range; S2: Severity threshold separating partially
symptomatic range from fully symptomatic range; t1, Start of MDD episode; t2, Start of episode remission; t3, End of episode
remission; t4, Relapse of MDD episode; t5: Start of episode recovery and end of MDD episode; t6, Start of MDD recurrence.
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World Health Organization, 1993), as summarised in
Table 1.
Methods/literature search
This systematic review largely adhered to PRISMA
guidelines (Moher et al. 2009). To review empirical evi-
dence regarding the definitions proposed by Frank
et al. (1991), we searched both Web of Science and
Pubmed for studies that referenced them without
imposing language restrictions (see supplementary
PRISMA flow diagram). Duplicates and non-
obtainable studies were excluded. Based on title and
abstract, studies were excluded that (i) did not focus
on individuals with MDD, (ii) were non-empirical,
(iii) were of study types not expected to be useful for
the purpose of this review (see online supplement),
or (iv) focused on the evaluation of some association
or cause-effect relation between variables.
The remaining articles were scrutinised for data that
could (in)validate at least one of Frank’s definitions.
Because severity related criteria were necessarily
instrument-specific we focused on articles determining
cut-offs on the HAMD-17 and the Montgomery-
Åsberg Depression Rating Scale (MADRS), which are
the most widely used instruments (Zimmerman et al.
2004a). Studies using different methodologies were
included (see results section). Criteria to define state
duration should be maximally predictive of remaining
in that state (Frank et al. 1991). Therefore, we sought
studies that show the remission/recovery and relapse/
recurrence of depressive episodes over time (via sur-
vival curves or equivalent).
Two authors (PLdZ, BFJ) extracted data inde-
pendently and resolved discrepancies through dis-
cussion and consensus. References of included
articles were searched for additional relevant
studies. The literature search was last updated on
August 30, 2017.
Results
The 1570 identified papers (supplementary eFigure)
included 214 duplicates and 26 non-obtainable papers.
The study selection criteria (as outlined above)
reduced the number to 117 papers and yielded 49 add-
itional records via reference checks. From these 166
papers, 110 were excluded based on the full-text
assessment. Thus 56 studies covering 39 315 subjects
were included, and summarised in Tables 2–5.
Severity thresholds
Frank et al. (1991) categorised the level of MDD symp-
tomatology in three clinical ranges: a fully symptomatic
range that can indicate the start of an episode, an
asymptomatic range that can indicate the start of a full
remission, and a partially symptomatic range in between.
The ‘asymptomatic range’ is supposed to represent the
normal range consistent with the absence of disorder.
The term is a bit of a misnomer as this range includes
the presence of a minor level of symptomatology asso-
ciated with the ‘healthy’ (non-depressed) population,
in which the average HAMD-17 score is about 3.2
(Zimmerman et al. 2004b); however, for consistency,
the term asymptomatic will be used throughout this
review.
Two instrument-specific ‘thresholds’ need to be
defined on the HAMD-17 and MADRS (most widely
used as endpoints in clinical trials; Zimmerman et al.
2004a) to operationalise these three different levels of
symptomatology (see Fig. 1). Frank et al. (1991) defined
HAMD-17 scores515 to correspond to the fully symp-
tomatic range while HAMD-1747 would indicate the
Table 1. Comparison DSM-5 and ICD-10 definitions for depression concepts
Minimal consecutive time duration: DSM-5 ICD-10
Episode D Symptomatic range 2 weeks 2 weeksa
Remission E Asymptomatic range 2 months Not explicitly definedb
Recovery F Asymptomatic range Not explicitly definedb Not explicitly definedb
Asymptomatic Range cut-off 42 symptoms to no more than
a mild degree
‘Free from any significant mood
symptoms’, not specified further
Symptomatic Range cut-off 51 out of 2 core symptoms and
55 out of 9 total symptoms
52 out of 3 core symptoms and
54 out of 10 total symptoms
aIf the symptoms are particularly severe and of very rapid onset, it may be justified to make the diagnosis after less than 2 weeks.
bAlthough the term ‘recovery’ is mentioned in the DSM-5 and ICD-10, it is not explicitly defined. ‘Relapse’ is not mentioned in
DSM-5 and ICD-10, whereas a recurrent episode is defined in DSM-5 as a return of symptoms during a remission (i.e. equivalent
to the concept of ‘relapse’ by Frank et al. (1991)) and in ICD-10 as a depressive episode separated from a previous episode by at
least 2 months free from any significant mood symptoms.
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asymptomatic range, the latter of which is roughly
equivalent to MADRS 410–11 (Zimmerman et al.
2004c).
Regarding the severity thresholds, the 32 studies
that provided data are summarised in Tables 2–4.
Severity threshold for the asymptomatic range
Studies focusing on the asymptomatic threshold could
be roughly divided into three groups, reflecting differ-
ences in the used criteria for determining the ‘best’
threshold for the asymptomatic range.
The first group of studies selected the optimal
threshold by maximising the correspondence to some
gold standard (Hawley et al. 2002; Zimmerman et al.
2004d, 2005; Bandelow et al. 2006; Ballesteros et al.
2007; Riedel et al. 2010; Romera et al. 2011; Leucht
et al. 2013; Sacchetti et al. 2015), most often the
Clinical Global Impression-Severity scale (CGI-S) or
some measure of functioning (see Table 2). The second
group of studies based on the optimal asymptomatic
threshold on the mean scores or statistical upper limits
of the general population (Zimmerman et al. 2004a, b;
see Table 3). These two groups mentioned a variety of
optimal asymptomatic thresholds for the HAMD-17
ranging from 42 (Zimmerman et al. 2005) to 410
(Zimmerman et al. 2004b) and for the MADRS 44
(Zimmerman et al. 2004a, 2004d) to 411 (Bandelow
et al. 2006).
The third and largest group of studies compared the
prognosis of patients with different levels of depres-
sive symptomatology, usually in terms of relapse/
recurrence risk (see Table 4). Based on this informa-
tion, a threshold can be chosen that best distinguishes
those with a favourable from those with a bad progno-
sis, argued by Zimmerman et al. (2004a) to be the best
method of validating a threshold. Most of these studies
show that the presence of ‘subthreshold’ symptoms
(often called residual symptoms if occurring after an
MDD episode) was associated with an enhanced risk
of a (recurrent) episode or relapse (Maier et al. 1997;
Riso et al. 1997; Judd et al. 1998, 2000, 2016; Van
Londen et al. 1998; Fava et al. 1999; Kanai et al. 2003;
Taylor et al. 2004; Nierenberg et al. 2010; Dunlop
et al. 2012; Kiosses & Alexopoulos, 2013; Peselow
et al. 2015). One study (Romera et al. 2011) did not
find this increased risk. Often authors implicitly
argued for a lower threshold for remission that does
not encompass this level of symptomatology. Some
studies also showed that remission as defined by
Frank et al. (1991), HAMD-17 47, is associated with
a better prognosis than not achieving this level of
remission (Paykel et al. 1995; Pintor et al. 2004).
Saliently, some other noteworthy studies showed a
large discrepancy between Frank’s definition of
depression and patient’s own judgement regarding
their remission (Zimmerman et al. 2012a, b). Within
the group of remitters as defined by Frank et al.
(1991), a substantial heterogeneity was observed with
respect to reported symptoms (Zimmerman et al.
2012c), psychosocial impairment (Zimmerman et al.
2004e, 2007) and a range of other relevant outcomes
(Zimmerman et al. 2012d) (see Table 3).
Severity threshold for the fully symptomatic range
Only one study focusing on the fully symptomatic
threshold was obtained (see Table 2). By using the
CGI-S of 2 or 3 as the gold standard, Leucht et al.
(2013) advise a HAMD-17 threshold of 57 or 514,
respectively.
Duration threshold for episode
Frank et al. (1991) categorised the symptomatic period
following any non-depressive state using a time
boundary, separating the time period before the symp-
toms were recognised as part of a depressive episode
from the time period afterwards. The underlying
assumption was that developing transient depressive
symptoms is not necessarily pathological, as long as
they do not culminate in a long-lasting depressive epi-
sode. Regarding the validation of this duration criter-
ion, Frank et al. (1991) state that an episode should
be declared ‘when it is unlikely that the patient will spon-
taneously recover in the next day or two’. Although rather
arbitrary, the concept is clear: for the validation of this
duration criterion, data are necessary that shed light on
the prognosis of those with recently started depressive
symptomatology.
Such data was provided by four studies (see
Table 5). The meta-analysis by Whiteford et al. (2013)
covering the rate of spontaneous remission in untreated
depression showed that this rate decreases continuously
over time. However, the amount of data in the range of
short duration of follow-up is rather scarce and the
studied population (wait-list and primary care samples)
is not representative of the general population with
depressive symptoms.
One study in the general population showed that
25% of depressive episodes remitted after 4 weeks
and 50% after 8–12 weeks, using a methodology in
which onset and end of depressive episodes were
retrospectively assessed by asking the respondents
for their depressive symptomatology in the past
(Eaton et al. 1997). The finding of a median duration
of 12 weeks was replicated in the NEMESIS study
using a similar methodology, which also shows that
the rate of recovery quickly diminishes after these 12
weeks (Spijker et al. 2002).
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Table 2. Asymptomatic threshold (above) and fully symptomatic threshold (below): Comparisons with a gold standard






M (S.D.) at T1)
Scale to determine
cut-off
Gold standard for asymptomatic
range/remission
Advised or implicated cut-off
for asymptomatic range
Asymptomatic
Hawley et al. 2002 Patients, GB 684 N/A N/A MADRS CGI-S (using two different methods;
CGI-S = 2 interpreted as ‘midpoint’
between remission and no remission)
MADRS <9 or <10
Zimmerman et al. 2004d Patients, USA 303 62 M = 43 (13) R = 18–79 MADRS Broad: SCOR-D42 MADRS49
Narrow: SCOR-D = 1b MADRS44b
Zimmerman et al. 2005 Patients, USA 303 62 M = 43 (13) R = 18–79 HAMD-17 Broad: SCOR-D42 HAM-D1745
Narrow: SCOR-D = 1b HAM-D1742b
Bandelow et al. 2006 Patients, DK/DE 1922 ± 70 M = ± 40 (12) MADRS CGI-S 42 MADRS411
CGI-S = 1 (not at all ill) MADRS45
Ballesteros et al. 2007 Patients, ES 113 81 M = 45 (13) HAMD-17 CGI-S = 1 HAMD-1747c
Riedel et al. 2010 Patients, DE 846 62 M = 46 (12) HAMD-17, MADRS CGI-S = 1 (=normal /min. Sx) HAMD-1746 MADRS47
Romera et al. 2011 Patients, ES 292 77 M = 51 (15) HAMD-17 SOFAS580 HAMD-1745d
Leucht et al. 2013 Patients, GB 7131 62 M = 45 (15) HAMD-17 CGI-S = 1 HAMD-1745
CGI-S 42 HAMD-1747




Leucht et al. 2013 Patients, GB 7131 62 M = 45 (15) HAMD-17 CGI-S 5 2 HAMD-175 7
CGI-S53 HAMD-17513/14
CGI-S, Clinical Global Impression – Severity scale (1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; 7=very much
worse); HAMD, Hamilton Rating Scale for Depression (a.k.a. HRSD, HDRS); MADRS, Montgomery–Åsberg Depression Rating Scale; M, mean; min., minimal; N, number of participants;
N/A, not available; R, range; S.D., standard deviation; SF-12 , 12-item short-form health survey; SOFAS, Social and Occupational Functioning Assessment Scale; Sx, symptoms; T1, baseline.
aCountry codes (ISO Alpha-2 and 3): DE, Germany; DK, Denmark; ES, Spain; IT, Italy; USA, United States of America.
bcut-off preferred by authors, typically because this subgroup scored better on psychosocial functioning.
cHigh value attributed to specificity.
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Advised or implicated cutoff for
asymptomatic range
Comparison with general population
Zimmerman et al. 2004a 569 31 M = 34 (8) MADRSa Gen.pop. mean 44
Gen.pop. mean + 1 SD 410, or upper limit of normal values
Zimmerman et al. 2004b 1014 51 M = 40 (12) HAMDa Gen.pop. mean HAMD-1744 (slightly higher than Gen.
pop. mean)
Gen.pop. mean + 1 SD HAMD-1747
Gen.pop. mean + 2 SD HAMD-17410
Other comparisons
Zimmerman et al. 2004e Patients, USA 117 62 M = 43 (13), R = 18-79
Zimmerman et al. 2007 Patients, USA 50 62 M = 43 (13), R = 18–73
Zimmerman et al. 2012a Patients, USA 140 68 M = 50 (13)
Zimmerman et al. 2012b Patients, USA 63 65 M = 48 (14)
Zimmerman et al. 2012c Patients, USA 140 68 M = 50 (13)
Zimmerman et al. 2012d Patients, USA 142 68 M = 49 (14)
Gen.pop., general population; HAMD, Hamilton Rating Scale for Depression (a.k.a. HRSD, HDRS); MADRS, Montgomery–Åsberg Depression Rating Scale; M, mean; min., minimal; N,
number of participants; N/A, not available; R, range; S.D., standard deviation; Sx, symptoms; T1, baseline. USA, United States of America.
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Age (range & M (S.D.)
at T1)
Definition for bad prognosis (e.g. relapse,
recurrence, episode)
Cut-off that distinguishes between good
and bad prognosis
Paykel et al. 1995 Patients, GB 57 61 R = 18–65 RDC MDD 51 month HAMD-1747
Maier et al. 1997 Gen.pop. & patients, DE 400 N/A N/A DSM-3-R MDD <3 DSM MDD Sx
Riso et al. 1997 Patients, USA 90 56 M = 38 (10) HAMD-17514 for 52 week HAMD-1746
Judd et al. 1998 Patients, USA 237 63 M = 40 (15) MDD PSR 5 or 6 for5 2 week (claim to
use RDC criteria)
MDD PSR = 1; authors argue recovery
should be defined as PSR = 0b
Van Londen et al. 1998 Patients, NL 49 59 M = 45 DSM-3-R MDD 5 1 month MADRS <2 per Sx
Fava et al. 1999 Patients, IT 40 N/A N/A N/A N/A
Judd et al. 2000 Patients, USA 96 60 M = 40 (15) Unclear Unclear
Kanai et al. 2003 Patients, JP 82 59 M = 44 (15) Subthreshold’ Ex (53 DSM-4 Sx OR51
DSM-4 Sx that were graver than mild
degree) for51 month
HAMD-1741
Pintor et al. 2004 Patients, ES 138 68 M = 53 (16), R518 HAMD-17515 (Frank criteria) HAMD-1747
Taylor et al. 2004 Patients, USA 153 65 M = ± 69 MADRS > 15 MADRS lowerc
Nierenberg et al. 2010 Patients, USA 943 N/A M= 40, R = 18–75 QIDS-SR16 511 (according to authors
about HAMD-17514)
No clear cut-offd
Romera et al. 2011 Patients, ES 292 77 M = 51 (15) CGI-S increase52 points and DSM-4
MDD criteria
Future relapses were not significantly
predicted by certain cut-offs, probably
due to the small number of relapses.
Dunlop et al. 2012 Patients, USA 258 68 M = 42, R = 18–65 HAMD-17 >12 and a < 50% decrease from
Ex T1 at 2 consecutive visits or at the
last visit before discontinuation.
HAMD-1743
Kiosses & Alexopoulos 2013 Patients, USA 152 60 M = 72 (7), R = 60–89 PSR score55b LIFE-PSR42b
Peselow et al. 2015 Patients, USA 387 59 M= 32 (12), R = 16–77 Not clearly indicated; MADRS515 or
meeting DSM-4 criteria for MDD.
MADRS48
Judd et al. 2016 Patients, USA 322 60 M = 40 (15), R = 17–76 PSR-MDD = 5/6 or PSR = 3b for52 week PSR = 1b
DSM, Diagnostic and Statistical Manual; Ex., Episode; Gen.pop., General population; HAMD, Hamilton Rating Scale for Depression (a.k.a. HRSD, HDRS); LIFE-PSR, Longitudinal
Follow-up Examination (LIFE) Psychiatric Status Rating Scale (PSR); MADRS, Montgomery–Åsberg Depression Rating Scale; M, mean; min., minimal; N, number of participants; N/A,
not available; R, range; PSR, Psychiatric Status Ratings**; RDC, Research Diagnostic Criteria; S.D., standard deviation; Sx, symptoms; T1, baseline; QIDS-SR16, Quick Inventory of
Depressive Symptomatology 16-item self-rating scale.
aCountry codes (ISO Alpha-2 and 3): DE, Germany; ES, Spain; GB, United Kingdom; IT, Italy; JP, Japan; USA, United States of America.
bPsychiatric status ratings: (1) asymptomatic (return to usual self); (2) residual/mild affective Sx; (3) partial remission, moderate Sx or impairment; (4) marked/major Sx or impairment; (5)
meets definite MDD criteria without prominent psychotic Sx or extreme impairment; (6) meets definite criteria with prominent psychotic Sx or extreme impairment.
cThe authors state that relapse becomes less likely when the MADRS score is lower, but there is no single cut-off that has high sensitivity and specificity for predicting relapse: ‘This suggests
that there is no particular cut-off that is sufficient to consider as ‘low enough’ to protect against future relapse, so the primary conclusion would be to strive for the lowest score possible’.
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Table 5. Definitions of duration thresholds for episode, remission and recovery of major depressive disorder
First author Year
Sample,




M (S.D.) at T1)
Estimated
point of
rarity Episode Remission Recovery Relapse Recurrence
Duration thresholds for episode
Eaton et al. 1997 Gen.pop., USA 71 75 R = 18–70 Sadness/anhedonia
& 2 other Sx
N/A ≥1 year without
depressive Ex
N/A First Ex after recovery
Spijker et al. 2002 Gen. pop., NL 250 67 R = 18–64 DSM-3-R def. via
CIDI
No/min. depressive











2013 Patients, USA 88 73 R = 18–98,
M = 37
≥2 week sadness &
≥4 Sx of adequate
severity
Ex before T1, but
not at T1
interview




2013 Patients, USA 749 73 M = 34 Differs per study Differs per study N/A N/A N/A
Duration thresholds for remission and recovery










≤2 Sx MDD crit. B
(each HAMD ≤1)
N/A MDD Ex after
recovery







2 week of meeting






Paykel et al. 1995 Patients, USA 57 61 N/A ±10 month RDC MDD Dx 2 month Sx below
MDD criteria
(retrosp. ass.)
N/A Return to RDC
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M (S.D.) at T1)
Estimated
point of
rarity Episode Remission Recovery Relapse Recurrence




N/A 1 yearr in which
there was no
MDD Ex
N/A First Ex after recovery



























≥1 week & HAMD
≥16 within 16 week
after MDD
remission




Riso et al. 1997 Patients, USA 90 56 M = 38 (9.7) ±3 month Not def., but
inclusion RDC &
HAMD ≥14




≥14 after 6 month
of recovery
Judd et al 1998 Patients, USA 237 63 M = 40 (15) ±29–37
month
RDC: >2 week










>2 week MDD PSR 5
or 6b (RDC def.)
>2 week MDD PSR 5
or 6b (RDC def.)


























1998 Patients, NL 49 59 45 ±4 month DSM-3-R criteria
for MDD






(1 MADRS Sx = 3
allowed if rest
<3)
Full remission ≥ 6
month
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Mueller et al. 1999 Patients, USA 380 61 M = 38 No explicit def. N/A The first of 8 wk of
no/min. Sx
















No focus on recovery 2 week re-appearance
of HAM-D scale ≥17
within 6 month of
remission onset
N/A
Solomon et al. 2000 Ex-patients,
USA
318 59 M = 39 Dx made according
to RDC (not
further specified)
N/A ≥8 week no MDD Sx
or ≤2 Sx at mild
level (PSR)b
N/A Reappearance of RDC
MDD criteria
≥2 week after being
recovered from
preceding Ex
Heinze et al. 2002 Patients, MX 228 85 N/A ±12 month DSM (not further
specified)
Unclear Unclear Unclear Unclear




≤2 mild MDD Sx
No focus on relapse.
[3]
DSM-4 MDD
Kennedy et al. 2003 Patients, GB 65 61 M = 41,
R = 20–65
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No explicit def. No explicit def. No explicit def. No explicit def. Ex
after an earlier Ex
with a ‘well period’
in-between. [4]
















N/A DSM-4 Ex after
achieving remission.
Partial relapse >min.
Sx but not fulfilling
criteria Ex.
N/A









when none of the
9 core Sx was
rated. Partial
remission ≤4 Sx.
N/A 2 week return to
DSM-4 MDD within
2 month after being
below threshold
Return to Ex MDD
after ≥2 month of
partial/full
remission






≥3 month with a PSR
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2 week HAM-D <8 N/A Reappearance of Sx







Dunlop et al. 2012 Patients, USA 258 68 M = 42,
R = 18–65








(≥8 week i.e. 56




acute phase T1 at 2
consecutive visits







2012 Patients, ES 127 66 65 DSM-4-TR HAMD-21 ≤6; no
duration
criterion def.




within 6 month after
remission
Emergence of a new





2013 Patients, USA 152 60 M = 72 (7),
R = 60–89




































MADRS ≤8 Relapse and recurrence
not distinguished
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M (S.D.) at T1)
Estimated
point of
rarity Episode Remission Recovery Relapse Recurrence
Judd et al. 2016 Patients, USA 322 60 M = 40 (15),
R = 17–76
RDC criteria ≥2














first of 2 week with
syndromal MDD Sx





first of 2 week with
syndromal MDD Sx
(PSR = 5 or 6) or
minor depression
(PSR = 3)b.
ass., assessment; DSM, Diagnostic and Statistical Manual; CIDI, Composite International Diagnostic Interview; Dx, diagnosis; def., definition; Ex., Episode; Gen.pop., General population;
HAMD, Hamilton Rating Scale for Depression; LCI, Life chart interview; M, mean; MDD, Major Depressive Disorder or unipolar depression; min., minimal; N, number of participants; N/A,
not available; NIMH, National Institute of Mental Health; PSR, Psychiatric Status Ratingsb; R, range; RDC, Research Diagnosis Criteria; retr., retrospectively; SADS-L, Schedule for Affective
Disorders and Schizophrenia-Lifetime interview; S.D., standard deviation; Sx, symptoms; T1, baseline wave; T2, follow-up wave.
aCountry codes (ISO Alpha-2 and 3): CA, Canada; DE, Germany; DK, Denmark; ES, Spain; FI, Finland; GB, United Kingdom; IE, Ireland; IT, Italy; JP, Japan; MX, Mexico; NL, Netherlands;
SE, Sweden; USA, United States of America.
bPsychiatric status ratings: (1) asymptomatic (return to usual self); (2) residual/mild affective Sx; (3) partial remission, moderate Sx or impairment; (4) marked/major Sx or impairment; (5)
meets definite MDD criteria without prominent psychotic Sx or extreme impairment; (6) meets definite criteria with prominent psychotic Sx or extreme impairment.
(1) Respondents rated whether they experienced ‘a time when you felt sad or blue and had some of these other problems (e.g., weight loss or sleeplessness)’.
(2) Response was defined in various ways, and each definition was tested for validity.
(3) Authors appear to mix up recurrence and relapse, but we denote time after patient recovered as recurrence.
(4) Medication use was seen as indication for not being healthy, thus these people were not at risk for recurrence.
(5) PSR ≥3 during some of these weeks count as residual Sx after remission, i.e., the patient is not yet considered to be relapsed or recurred before PSR ≥5.
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Wakefield & Schmitz (2013) argued that ‘uncompli-
cated’ depressive episodes, defined as <2 months in
duration combined with the absence of certain
‘heavy’ symptoms such as suicidal ideation and psy-
chomotor retardation, should not be classified as
MDD. They argued that the risk of developing new
depressive episodes for those who had such an uncom-
plicated episode is not higher than for the general
population. Thus, this subgroup of patients does not
seem to suffer from an underlying disorder that
increases their risk of developing subsequent depres-
sive episodes. This suggests that, at least for this sub-
group, the depressive symptomatology should be at
least 2 months of duration before it should be consid-
ered as a depressive episode.
Duration thresholds for remission and recovery
Frank et al. (1991) categorised the asymptomatic period
following a fully symptomatic period with two time
boundaries, yielding three distinct time periods:
those (i) before the onset of full remission, (ii) follow-
ing the onset of full remission but before declaration
of recovery and (iii) after declaration of recovery. The
underlying assumption is that these three successive
periods are each associated with a certain ‘hazard’
for a return of symptoms, which diminishes signifi-
cantly at each time boundary and becomes constant
when recovery is declared.
In the available literature, the hazard for a return of
symptoms for asymptomatic individuals is usually
shown indirectly in the form of survival curves, show-
ing the fraction of subjects without relapse/recurrence
over time. An exponential survival curve is thus
equivalent to a constant hazard, whereas a sudden
decrease in a hazard (for example, when remission is
achieved) should be visible as an upward discontinu-
ity in the survival curve slope.
Survival curves (or equivalent) for asymptomatic
individuals until relapse/recurrence or equivalent
data were obtained from 31 studies (see Table 5).
There is a substantial difference between studies in
their studied populations (viz., general population,
1st, 2nd or 3rd line ambulant patients or inpatients),
their operationalisations of remission, recovery, relapse
and recurrence (because of different instruments or
cut-offs on the same instruments) and in the involved
treatments that are often uncontrolled.
Several studies show some indication of a sudden
drop in relapse/recurrence rate a certain time after
remission/recovery was obtained (Paykel et al. 1995;
Riso et al. 1997; Judd et al. 1998; Van Londen et al.
1998; Heinze et al. 2002; Kanai et al. 2003; Kennedy
et al. 2003; Naz et al. 2007; Holma et al. 2008; de
Jonge et al. 2010; O’Leary et al. 2010; Kiosses &
Alexopoulos, 2013). However, the exact amount of
time necessary to achieve this drop (as counted from
the start of the asymptomatic period) differs per
study, ranging from about 2 months (O’Leary et al.
2010) to about 3 years (Judd et al. 1998). Other studies
do not find such a sudden drop at all, instead suggest-
ing that the diminishing hazard of return of symptoms
is a gradual process rather than a discrete one (Maj
et al. 1992; Shea et al. 1992; Flint & Rifat, 1997;
Kessing et al. 1998; Van Weel-Baumgarten et al. 1998;
Mueller et al. 1999; O’Leary et al. 2000; Solomon et al.
2000; Mattisson et al. 2007; Dunlop et al. 2012;
Martínez-Amorós et al. 2012; Seemüller et al. 2014;
Peselow et al. 2015; Judd et al. 2016). In particular, sev-
eral studies of the long-term course of MDD show that
recurrence rates stabilise only after many years, such
as 2.5 years (Solomon et al. 2000), 10 years (Mattisson
et al. 2007) or about 15 years (Kessing et al. 1998). A
third group of studies shows atypical survival curves
where the time-specific risk of return of symptoms
even increases over time during certain time intervals
(Eaton et al. 1997; Emslie et al. 1997; Birmaher et al.
2004; Pintor et al. 2004; Yiend et al. 2009).
Discussion
Severity thresholds
The obtained studies that aimed to identify the optimal
thresholds for the asymptomatic and fully symptom-
atic depressive ranges differed widely in their method-
ologies (see Tables 2–4). Frank et al. (1991) postulated
that these ranges should (i) correspond to what clini-
cians view as asymptomatic and fully symptomatic
and (ii) that classification of patients within these
ranges should be reasonably stable over time. Other
theorists argued that the optimal thresholds should
be selected based on their predictive value for the
future course (Zimmerman et al. 2004e), which would
be most consistent with methods used in other medical
fields (Zimmerman et al. 2004a).
Severity threshold for the asymptomatic range
Multiple studies showed that those who scored below
a certain threshold on depressive symptom scales had
a better prognosis than those who scored above it
(Paykel et al. 1995; Maier et al. 1997; Riso et al. 1997;
Judd et al. 1998; 2000, 2016; Van Londen et al. 1998;
Fava et al. 1999; Kanai et al. 2003; Pintor et al. 2004;
Taylor et al. 2004; Nierenberg et al. 2010; Dunlop
et al. 2012; Kiosses & Alexopoulos, 2013; Peselow
et al. 2015). Often this finding was presented as evi-
dence for the perspective that the asymptomatic
threshold is currently too high (Judd et al. 1998).
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However, even though none of these studies systemat-
ically studied and compared the predictive value of all
possible thresholds, we hypothesise that this is a gen-
eral finding that can be obtained irrespective of the
chosen threshold, as a lower score on a depressive
symptom scale increases the ‘symptomatic distance’
to the fully symptomatic threshold and therefore the
average time required for reaching that state. Indeed,
some studies show that the currently often-used
threshold (HAMD-1747; Frank et al. 1991) also differ-
entiates in this regard (Paykel et al. 1995; Pintor et al.
2004). Studies using other methodologies for determin-
ing the best asymptomatic threshold – such as optimis-
ing correspondence to clinical impressions of clinicians
(using the CGI-S as a gold standard), different func-
tioning scales, or the general population – yield differ-
ent optimal thresholds. The consensus among these
authors seems to be that the currently often-used
threshold of HAMD-17 47 is too high, as it leads to
the inclusion of too many patients with poor function-
ing (Sacchetti et al. 2015), who are psychosocially
impaired (Zimmerman et al. 2007) and who do not
consider themselves as remitted (Zimmerman et al.
2012a).
Ultimately, the particular choice of asymptomatic
threshold is rather arbitrary given the available evi-
dence. Nonetheless, the currently often-used threshold
seems to be too high. We, therefore, suggest lowering
the asymptomatic threshold to 44 on the HAMD-17;
this is on the low side of the suggested values in the
obtained studies – which we think is justified given
the better functioning below this score (Sacchetti et al.
2015) – although still above the mean score in the gen-
eral population (Zimmerman et al. 2004b). It has been
shown that some patients who scored 47 on the
HAMD-17 still met diagnostic criteria for MDD
(Zimmerman et al. 2004e), which is another argument
for our suggestion to lower the asymptomatic thresh-
old to 44, as this largely prevents ‘remitted’ people
from meeting the diagnostic criteria for MDD. This
new HAMD-17 threshold is roughly equivalent to a
threshold of 45 on the MADRS (Mittmann et al.
1997), which is plausible given the reviewed evidence.
Note that these thresholds are useful as endpoints in
clinical studies, but do not necessarily mean that scor-
ing below these thresholds should be the main treat-
ment goal for clinicians, as treating individual
patients by striving for the lowest score possible still
improves prognosis (Taylor et al. 2004).
Severity threshold for the fully symptomatic range
Only one study was obtained that provides some evi-
dence for the fully symptomatic cut-off (Leucht et al.
2013). This relative lack of evidence is understandable,
as this seems to be the definition that least ‘needs’
empirical validation; this can be understood as a rather
subjective clinical decision regarding the minimal level
of symptomatology that can be considered to be a dis-
order. Therefore, there is not enough evidence to make
any recommendations regarding this threshold.
Duration threshold for episode
Only a limited amount of studies showed data on the
prognosis of those with ‘recent-onset’ depression (see
Table 5). This can be explained by epidemiological
investigations that typically include depressed popula-
tions, for which it is unclear how long the depressive
symptoms have been present at the start of the studies.
Although two studies show that half of the depressive
episodes in the general population remit within 3
months after their onset (Eaton et al. 1997; Spijker
et al. 2002), it seems likely that many short ‘episodes’
of only a few days are missed since these episodes
are infrequently retrospectively indicated, and short
episodes are more easily forgotten than long ones
(Moffitt et al. 2010). Therefore, the rate of early remis-
sion is probably even higher than suggested by these
studies.
In general, the reviewed data suggest that the rate of
(spontaneous) remission of depressive symptoms is
relatively high when the onset of these symptoms is
recent, especially during the first 12 weeks, but
diminishes quickly thereafter. This provides some jus-
tification for the suggestion by Frank et al. (1991) of
requiring a certain amount of time at the fully symp-
tomatic level before defining a depressive episode.
However, the currently required ‘waiting time’ of
only 2 weeks (see Table 1; DSM-5 criteria, APA,
2013; ICD-10 criteria, WHO, 1993) does not seem to
be based on empirical evidence. The reviewed studies
suggest that a longer time period might be advisable.
Nonetheless, we refrain from a definitive conclusion,
for which a prospective study in which the general
population is screened with a high frequency (e.g.
weekly) for depressive symptomatology is required
but hitherto unavailable.
Duration thresholds for remission and recovery
A substantial body of literature studying depressive
relapse/recurrence risk over time has been obtained
(see Table 5), but comparing the studies is not straight-
forward; the studies differed in their studied popula-
tions, their operationalisations of remission, recovery,
relapse and recurrence, and in the involved treatments.
Some studies were consistent with the idea of a ‘point
of rarity’ (Frank et al. 1991) at which the relapse/recur-
rence risk suddenly drops or becomes stable.
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However, there is no consistency in the estimation of
this time point. Combined with the fact that the major-
ity of studies do not show such a point of rarity, the
most likely conclusion is that prognosis gradually
improves as remission/recovery duration is longer,
rather than suddenly at a particular point in time.
The reviewed data do not suggest that any specific
duration threshold to distinguish remission from recov-
ery is warranted to add predictive value to the observa-
tion that prognosis improves over time as the duration
of the asymptomatic period increases. Not only were
the specific operationalisations of the duration criteria
by Frank et al. (1991) and Rush et al. (2006) not empiric-
ally supported, it seems that the whole concept of these
duration criteria must be rejected. The idea that a
reoccurrence of depressive symptoms shortly after
their initial remission constitutes a ‘relapse’ of the previ-
ous episode, whereas their later reoccurrence is the first
sign of an entirely new episode, is a model that lacks
empirical support. Additionally, it is of no additional
value to the patient or clinician as the assumed origin
of the reoccurring symptoms has no implications for
treatment or prognosis.
Thus, based on these results, the duration criteria for
declaring remission and recovery seem unnecessary.
We suggest that depressive remission can simply be
defined as the asymptomatic state after a depressive
episode, without applying any duration criterion.
Stability of remission is then relatively low on the
first day but increases gradually with its duration.
The term recovery can then be used as a concept that
includes more than just absence of symptoms, such
as social functioning or subjective well-being, possibly
including the absence of significant treatment as this
would better fit the concept of recovery from a
patient’s perspective.
Limitations
Limitations of this review include the greatly varying
study populations and treatments within the included
studies (which is also a strength). Moreover, a substan-
tial part of the data had to be extracted from survival
curves that only rarely showed confidence intervals
and often did not possess a clearly labelled time axis,
making it difficult to assess exactly when the measure-
ment began.
Conclusions
More than a quarter-century after the landmark paper
in which Frank et al. (1991) provided their consensus-
based definitions for depressive states (episode, remis-
sion, recovery, relapse, recurrence), we reviewed the
empirical evidence. The data suggest that remission
can best be defined as a less symptomatic state than
assumed earlier (HAMD-17 44 instead of 47), with-
out applying a duration criterion. Specific duration
thresholds to separate remission from recovery are
not meaningful. Evidence suggests that the minimal
duration of depressive symptoms before a depressive
episode can be defined should be longer than 2
weeks, although further studies are required to recom-
mend an exact duration threshold.
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